By liquid chromatography–mass spectrometry (LC–MS/MS) analysis of plasma samples, Cohen and colleagues [29] demonstrated that a subset of peptides, corresponding to α-1-microglobulin/inter-α-trypsin inhibitor light chain precursor, gelsolin, clusterin, and biotinidase, classifies BC patients into two histological types: infiltrating ductal carcinomas and invasive mammary carcinomas with a lobular, tubular, mucinous, or medullary histotype. Here, CLU is linked to invasive breast carcinoma.